- জেনেরিক নাম
- Streptokinase
- শক্তি
- 15 Lac IU
- ডোজ ফর্ম
- Injection
- প্রস্তুতকারক
- Advanced Chemical Industries PLC
Streptokinase IV Injection
Streptokinase IV 15 Lac IU Injection সম্পর্কে
বাংলাদেশে Streptokinase IV 15 Lac IU Injection ইনজেকশন হিসেবে পাওয়া যায়; এতে Streptokinase আছে (১৫ Lac IU)। Streptokinase IV প্রস্তুত করেছে Advanced Chemical Industries PLC। Streptokinase-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।
Streptokinase IV 15 Lac IU Injection কী?
Streptokinase IV 15 Lac IU is an injectable fibrinolytic (thrombolytic) medicine from Advanced Chemical Industries PLC. It works by helping the body turn plasminogen into plasmin, which breaks down clots. It is used in hospital for conditions such as acute myocardial infarction and for dissolving intracoronary thrombi. Because it affects clotting and bleeding, it is given under close medical supervision. Only a qualified doctor decides whether it is suitable, how it is prepared and how it is given. Ask the treating doctor or pharmacist about anything you do not understand.
Streptokinase IV-এর ব্যবহার
Streptokinase IV is used in the management of acute myocardial infarction and for the lysis of intracoronary thrombi. It is also used to improve ventricular function and to reduce mortality when given by the intravenous or intracoronary route. It belongs to the fibrinolytic (thrombolytic) group of medicines, which help break down blood clots. Only a doctor can decide whether this medicine is appropriate for a particular patient.
Streptokinase IV কীভাবে ব্যবহার করবেন
Streptokinase IV 15 Lac IU is given by a doctor or trained hospital staff, usually as an infusion into a vein or, in some cases, into a coronary artery. It is prepared by reconstitution before use. The doctor decides the dose, the rate and the length of the course, and adjusts them to the patient. Do not attempt to use or prepare this injection yourself. Ask the doctor or pharmacist if you have questions about how it is being given.
Streptokinase IV-এর পার্শ্বপ্রতিক্রিয়া
Common side effects include headache, back pain, muscle pain, chills, fever and a general feeling of tiredness. Bleeding can occur, including at the injection site, bruising, nosebleeds, and gastrointestinal or genitourinary bleeding. Less common but serious effects include bleeding inside the skull and other severe bleeding. Because of these risks, treatment is given with close medical monitoring. Tell the doctor or nurse straight away about any unusual bleeding, fever or feeling unwell during or after treatment.
সতর্কতা ও নিরাপত্তা
Streptokinase IV increases the risk of bleeding, so it is not suitable for people with existing or recent bleeding, bleeding disorders, a potential for internal bleeding, or reduced blood clotting. It is also not used after a recent stroke or recent head or facial injury, or after certain surgery. Pregnancy is category C, and it is not known whether it passes into breast milk; breastfeeding is usually stopped while a woman receives it. Tell the doctor about all medicines you take, including blood thinners, and about any past streptococcal infection or earlier streptokinase treatment. The doctor decides if it is safe for you.
সাধারণ প্রশ্ন
How is Streptokinase IV given?
It is given by a doctor or hospital staff, usually as an infusion into a vein or into a coronary artery, after being prepared by reconstitution. The doctor decides the dose, the rate and the length of the course. Do not use it yourself.
What is Streptokinase IV used for and what kind of medicine is it?
It is a fibrinolytic (thrombolytic) medicine. It is used in hospital in the management of acute myocardial infarction and for dissolving intracoronary thrombi, and to improve ventricular function and reduce mortality when given by the intravenous or intracoronary route.
Is Streptokinase IV safe in pregnancy or breastfeeding?
It is pregnancy category C. It is not known whether it passes into breast milk, so breastfeeding is usually stopped while a woman receives it. Tell the doctor if you are pregnant, may be pregnant or are breastfeeding, and the doctor will decide what is suitable.
What should I tell the doctor before receiving Streptokinase IV?
Tell the doctor about any bleeding problems, recent stroke, recent head or facial injury, recent surgery, and all medicines you take, especially blood thinners. Also mention any past streptococcal infection or earlier streptokinase treatment, as these can affect how well it works.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Streptokinase is indicated for use in the management of acute myocardial infarction, for the lysis of intracoronary thrombi, for the improvement of ventricular function, and reduction of mortality when administered by either the intravenous or intracoronary route. Earlier administration of streptokinase ... Read moreStreptokinase is indicated for use in the management of acute myocardial infarction, for the lysis of intracoronary thrombi, for the improvement of ventricular function, and reduction of mortality when administered by either the intravenous or intracoronary route. Earlier administration of streptokinase is correlated with greater clinical benefit, the greatest benefit (in terms of mortality reduction) being seen when Streptase is administered within the first 4 hours after onset of symptoms. The treatment should always commence within 6 hours of the onset of pain.ফার্মাকোলজি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Streptokinase forms a complex with plasminogen which then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins.মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Streptokinase can be reconstituted using 5 ml sodium chloride injection or 5% Dextrose Injection directing the diluent at the side of the vacuum packed vial rather than into drug powderAcute Myocardial Infarction:
IV infusion:- Vial size (IU): 15,00,000
- Total solution volume: 45 ml
- Infusion rate: Infuse 45 ml within 60 mins
- Vial size (IU): 2,50,000
- Total solution volume: 125 ml
- 20,000 IU bolus, Infusion rate: Loading dose of 10 ml
- 2,000 IU/min. for 60 minutes, Infusion rate: 60 ml/hour
Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thrombosis or Embolism:
- 2,50,000 IU loading dose over 30 min, Vial size (IU): 15,00,000, Total solution volume 90 ml, Infusion rate: Infuse 30 ml/hour for 30 min
- 1,00,000 IU/hour for maintenance dose, Infusion rate: Infuse 6 ml/hour
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
There is an increased risk of haemorrhage in patients simultaneously or previously receiving anticoagulants (such as Heparin or Coumarin derivatives) or drugs which inhibit platelet formation or function (e.g., Platelet aggregation inhibitors, Dextrans, Phenylbutazone, Dipyridamole, Non-steroidal anti-inflammatory drugs). The effect of Heparin can be neutralized rapidly by administration of Protamine Sulphate. The Thrombin time (TT) should not be more than twice the normal control value before thrombolytic therapy is started. In the case of prior treatment with coumarin derivatives, the International Normalized Ratio (INR) must be less than 1.3 before starting Streptokinase infusion.Combination of Streptokinase with Aspirin for treatment of Myocardial infarction: Study showed a significant benefit to patients treated with these two agents after acute myocardial infarction. Mortality (both short and longer term) was reduced in these patients to a greater extent than in those treated with either agent alone.
Unless contraindicated, the concomitant use of Acetylsalicylic acid (ASA, Aspirin), starting prior to Streptokinase infusion and continued for one month thereafter may be instituted at the discretion of the physician. The benefit of combination therapy should therefore be weighed against the risk of increased haemorrhage.
Anticoagulation treatment following Streptokinase: Following high dose (1.5 million IU), short term treatment with Streptokinase, for acute myocardial infarction, the use of subsequent anticoagulant treatment has not yet been shown to be of unequivocal benefit. Therefore, in this situation, the use of anticoagulants should be decided by the physician.
প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
As thrombolytic therapy increases the risk of bleeding, Streptokinase, administered either systemically or locally, is contraindicated in the following situations:Existing or recent haemorrhage and haemorrhagic diathesis (with the exception of consumption coagulopathy) Potential for internal bleeding (e.g., peptic ulcer, ulcerative colitis, diverticulitis or visceral tumours) All forms of reduced blood coagulability, in particular spontaneous fibrinolysis and extensive clotting disorders.
Recent (within 2 months) cerebrovascular accident, recent (within 10 days) facial or head trauma, intracranial or intraspinal surgery, known intracranial neoplasm and all known neoplasms with risk of haemorrhage
Invasive operations, e.g., recent organ biopsy, invasive diagnostic procedure, recent implantation of a vessel prosthesis, long-term traumatic closed-chest massage or other recent surgery (until the 6th to 10th post operative day, depending on the severity of surgical intervention)
Arteriovenous malformation or aneurysm: Haemorrhagic diathesis including thrombocytopenia or pronounced hepatic or renal dysfunction
Severe uncontrolled hypertension (systolic BP > 200 mm Hg, diastolic BP > 100 mm Hg), or hypertensive retinal changes grades III/IV), hypertonic fundus
Severe liver or kidney damage: Simultaneous treatment with oral anticoagulants (International Normalized Ratio (INR) >1.3)
Endocarditis or pericarditis (Immediately after streptococcal infections which have produced a high antiStreptokinase titre (acute rheumatic fever, acute glomerulo-nephritis, etc.). More than 5 days and less than 12 months since previous Streptokinase therapy.
পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
The following adverse reactions are based on experience from clinical trials and on post marketing experience of Streptokinase.General disorders:
- Common: Headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise.
- Common: Haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. Gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis.
- Uncommon: Intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. Blood transfusions are rarely required.
- Very common: Development of antistreptokinase antibodies
- Common: Allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension.
- Rare: Neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain.
- Very common: Hypotension, heart rate and rhythm disorders, angina pectoris.
- Common: Recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema.
- Uncommon: Cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism.
- Very rare: Non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction.
- Common: Nausea, diarrhoea, epigastric pain and vomiting.
গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pregnancy category C. It is not known whether Streptokinase is excreted in the breast milk, nor whether it has harmful effects on the newborn. In the absence of further information, it is recommended that breast-feeding be discontinued in women who are to receive Streptokinase.সতর্কতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Because of the increased likelihood of resistance, due to antistreptokinase antibodies, retreatment with Streptokinase or Streptokinase-containing products may not be effective if administered between five days and twelve months of prior Streptokinase administration or Streptococcal infections, such as Streptococcal pharyngitis, acute rheumatic fever or acute glomerulonephritis secondary to a Streptococcal infection.In principle, no thrombolytic treatment should be commenced before the 10th postoperative day. However, in cases of pulmonary embolism, the indication for earlier treatment may be very strong and after careful consideration of all the risks, Streptokinase may be given before the tenth postoperative day. The danger of bleeding from the operative area must, of course, be taken into account.
The danger of haemorrhage is increased by simultaneous or previous treatment with anticoagulants (e.g., Heparin) or substances which inhibit platelet formation or function. If the patient is under active heparinisation, it should be neutralised by the administration of protamine sulphate before the start of thrombolytic therapy.
Repeated Administration: After administration of Streptokinase, the titre of antistreptokinase antibodies begins to rise after approximately one week, reaching a peak at 2 to 3 weeks and remains elevated for 8 to 12 months. Because of the increased likelihood of resistance, Streptokinase may not be effective if given during this period.
মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
If uncontrollable bleeding occurs as a result of overdosage, Streptokinase infusion should be ceased immediately. Bleeding can be reversed and blood loss managed effectively with appropriate replacement therapy. Administration of aminocaproic acid or aprotinin may be useful.সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Streptokinase vial should be stored at 2 to 25° C. Once reconstituted with physiological saline, the physico-chemical stability has been demonstrated for 24 hours at 2 to 8° C. From a microbiological point of view and as Streptokinase 1500000 contains no preservative, the reconstituted product should be used immediately. If it is not administered immediately, storage shall not exceed 24 hours at 2 to 8° C. Keep out of the reach of children.ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।